Page 92 - MEMORIA ANUAL 2019 SEHH-FEHH

MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
C, Bernal del Castillo T, Galanopoulos A, Calabuig M, Bonadies N, Medina de Almei- da A, Cermak J, Jerez A, Montoro J, Cortés A, Avendaño Pita A, López Andrade B, Hellstrom Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Greil r. Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: an International Analysis of 950 Cases Coordi- nated By the AGMT Study Group.
– Ganster C, Schaab R, Shirneshan K, Eder LN, Mies A, Germing U, Elmaagacli A, Solé F, Palomo L, Kaivers J, Söling U, Lange F, Kröger N, Hertenstein B, Döhner K, Bug G, Hildebrandt B, Talló Parra M, Nickelsen M, Glass B, Platzbecker U, Bacher U, Braulke F, Schanz J, Haase D. TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Com- plex (>3 anomalies) Aberrant Karyotypes.
– Adema V, Palomo L, Kerr CM, Walter W, Przychodzen BP, Hutter S, Laframboise T, Díez-Campelo M, Mallo M, Nazha A, Xicoy B, Meggendorfer M, Carraway HE, Ha- ferlach C, Sekeres MA, Visconte V, Haferlach T, Solé F, Maciejewski JP. Molecular Dissection of Del5q: Distinction Between Primary and Secondary Del(5q) and Pathogenetic Implications.
– Adema V, Kerr CM, Walter W, Hutter S, Nagata Y, Awada H, Kongkiatkamon S, Snider C, Co M, Rainey M, Durmaz A, Meggendorfer M, Nazha A, Scott JG, Car- raway HE, Sekeres MA, Solé F, Haferlach T, Visconte V, Maciejewski JP. Can Mono- somy 7 be Targeted by Next Generation Cereblon-Modulating Agents?
– Adema V, Hershberger C, Walter W, Kerr CM, Hutter S, Nagata Y, Awada H, Kong- kiatkamon S, Snider CH, Co M, Meggendorfer M, Nazha A, Carraway HE, Sekeres MA, Solé F, Padgett R, Haferlach T, Maciejewski JP, Visconte V. Hotspot U2AF1 Mu- tations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors.
– Zurdo M, Hurtado López AM, Chen-Liang TH, Martínez-Banaclocha H, Palomo L, López Cadenas F, Lumbreras E, Xicoy B, Zamora L, Díez-Campelo M, Solé F, Pelegrín P, Jerez A. Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
– Prosper F. Transcriptional and gene regulatory networks in the aging-clonal hematopoiesis-myelodysplatic syndromes axis as a tool for identifying novel therapeutic targets.
GRUPO ESPAñOL DE SÍNDROMES MIELODISPLÁSICOS (GESMD)
92